← Back to Search

Virus Therapy

RiMO-401 for Solid Tumors

Phase 1

Recruiting

Research Sponsored by Coordination Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 45 days

Awards & highlights

Study Summary

This trial is testing the use of RiMO-401 with radiation in patients with advanced tumors. The study will use a specific dose of RiMO-401 injected directly into the tumor to determine the best

Who is the study for?

This trial is for adults with advanced or metastatic cancer that can't be cured by standard treatments. They should have a tumor suitable for injection and radiation, not previously treated in the last six months. Participants need to be relatively healthy (ECOG score 0-1), have recovered from past cancer therapies, expect to live at least 12 weeks, and have good organ function.Check my eligibility

What is being tested?

The study tests RiMO-401 combined with radiation on patients with advanced tumors. It's a single-arm trial where everyone gets the same treatment. The dose of RiMO-401 is increased step-by-step in groups of patients to find the safest and most effective level.See study design

What are the potential side effects?

Potential side effects are not explicitly listed but may include typical reactions related to intratumoral injections such as pain, swelling, infection risk at the injection site, and general side effects from radiation like fatigue, skin irritation, or nausea.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 45 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~45 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 45 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determination of Recommended Dose

Secondary outcome measures

Evaluation of Objective Response Rate (ORR)

Evaluation of Safety and Tolerability

Other outcome measures

Evaluation of Area Under the Curve (AUC)

Evaluation of Maximum Plasma Concentration (Cmax)

Trial Design

1Treatment groups

Experimental Treatment

Group I: RiMO-401Experimental Treatment1 Intervention

• Single intratumoral injection followed by radiation

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Coordination Pharmaceuticals, Inc.Lead Sponsor

5 Previous Clinical Trials

104 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are prospective participants currently able to enroll in this medical study?

"The current status on clinicaltrials.gov shows that this research is actively seeking participants. It was initially uploaded on February 22, 2024, and most recently modified on March 5, 2024."

Answered by AI

What is the total number of individuals who are currently enrolled as participants in this medical study?

"Indeed, the information on clinicaltrials.gov affirms that this medical study is actively seeking subjects. The trial was initially posted on February 22nd, 2024 and most recently updated on March 5th, 2024. Approximately two dozen participants are sought from a single designated site."

Answered by AI

What is the safety profile of RiMO-401 in individuals undergoing treatment?

"During this Phase 1 trial, our team at Power rated the safety of RiMO-401 as level 1 due to the scarcity of data backing its safety and effectiveness."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase I Study of RiMO-401 With Radiation in Advanced Tumors

2024. "Phase I Study of RiMO-401 With Radiation in Advanced Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06182579.

All > Chicago